Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006)

Objective:To describe the evolving epidemiology, management, and risk factors for death of invasive Candida infections in intensive care units (ICUs). Design:Prospective, observational, national, multicenter study. Setting:One hundred eighty ICUs in France. Patients:Between October 2005 and May 2006, 300 adult patients with proven invasive Candida infection who received systemic antifungal therapy were included. Interventions:None. Measurements and Main Results:One hundred seven patients (39.5%) with isolated candidemia, 87 (32.1%) with invasive candidiasis without documented candidemia, and 77 (28.4%) with invasive candidiasis and candidemia were eligible. In 37% of the cases, candidemia occurred within the first 5 days after ICU admission. C. albicans accounted for 57.0% of the isolates, followed by C. glabrata (16.7%), C. parapsilosis (7.5%), C. krusei (5.2%), and C. tropicalis (4.9%). In 17.1% of the isolates, the causative Candida was less susceptible or resistant to fluconazole. Fluconazole was the empirical treatment most commonly introduced (65.7%), followed by caspofungin (18.1%), voriconazole (5.5%), and amphotericin B (3.7%). After identification of the causative species and susceptibility testing results, treatment was modified in 86 patients (31.7%). The case fatality ratio in ICU was 45.9% and did not differ significantly according to the type of episode. Multivariate analysis showed that factors independently associated with death in ICU were type 1 diabetes mellitus (odds ratio [OR] 4.51; 95% confidence interval [CI] 1.72–11.79; p = 0.002), immunosuppression (OR 2.63; 95% CI 1.35–5.11; p = 0.0045), mechanical ventilation (OR 2.54; 95% CI 1.33–4.82; p = 0.0045), and body temperature >38.2°C (reference, 36.5–38.2°C; OR 0.36; 95% CI 0.17–0.77; p = 0.008). Conclusions:More than two thirds of patients with invasive candidiasis in ICU present with candidemia. Non-albicans Candida species reach almost half of the Candida isolates. Reduced susceptibility to fluconazole is observed in 17.1% of Candida isolates. Mortality of invasive candidiasis in ICU remains high.

[1]  Yee-Chun Chen,et al.  Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. , 2003, The Journal of antimicrobial chemotherapy.

[2]  Victoria J. Fraser,et al.  Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality , 2005, Antimicrobial Agents and Chemotherapy.

[3]  H. Danawi,et al.  Management of central venous catheters in patients with cancer and candidemia. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  S. Fridkin,et al.  Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003 , 2005, Journal of Clinical Microbiology.

[5]  B. Guidet,et al.  Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. , 2002, Journal of critical care.

[6]  J. Sobel,et al.  Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Kollef,et al.  Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia , 2007, Critical care medicine.

[8]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  T. Sorrell,et al.  Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections , 2004, Internal medicine journal.

[10]  C. d’Enfert,et al.  Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome , 2008, Intensive Care Medicine.

[11]  J. Serody,et al.  Intravascular Catheter Exchange and Duration of Candidemia , 1995 .

[12]  E. Johnson,et al.  Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990–9) , 2001, Epidemiology and Infection.

[13]  A. Sitges-Serra,et al.  Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy , 1997, Intensive Care Medicine.

[14]  M G Rinaldi,et al.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. , 1991, The New England journal of medicine.

[15]  K. Laupland,et al.  Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. , 2007, The Journal of antimicrobial chemotherapy.

[16]  R. Wenzel,et al.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Bassetti,et al.  Epidemiological trends in nosocomial candidemia in intensive care , 2006, BMC infectious diseases.

[18]  D. Pittet,et al.  Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  G. Jackson,et al.  Gram-Negative Bacteremia: I. Etiology and Ecology , 1962 .

[20]  J. D. De Waele,et al.  Effect of fluconazole consumption on long-term trends in candidal ecology. , 2006, The Journal of antimicrobial chemotherapy.

[21]  M. Cuenca‐Estrella,et al.  In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. , 2005, The Journal of antimicrobial chemotherapy.

[22]  W. Hope,et al.  Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. , 2002, The Journal of hospital infection.

[23]  P. Lipsett,et al.  Double-Blind Placebo-Controlled Trial of Fluconazole to Prevent Candidal Infections in Critically Ill Surgical Patients , 2001, Annals of surgery.

[24]  T. Peláez,et al.  Mixed fungemia: incidence, risk factors, and mortality in a general hospital. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Sfar,et al.  [Management of invasive candidiasis and aspergillosis in adults]. , 2004, Revue de pneumologie clinique.

[26]  A. Tortorano,et al.  European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. , 2002, The Journal of hospital infection.

[27]  J. Trupl,et al.  Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  E. Anaissie,et al.  The epidemiology of hematogenous candidiasis caused by different Candida species. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[30]  Shane Gillespie,et al.  Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  D. Church,et al.  Invasive Candida species infections: a 5 year population-based assessment. , 2005, The Journal of antimicrobial chemotherapy.

[32]  S. Fridkin,et al.  Impact of early central venous catheter removal on outcome in patients with candidaemia. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  J. Vincent,et al.  Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care , 1998, Intensive Care Medicine.

[34]  S. Lemeshow,et al.  A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. , 1993, JAMA.

[35]  J. Serody,et al.  Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  E. Anaissie,et al.  Should vascular catheters be removed from all patients with candidemia? An evidence-based review. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.